Key result
This review provides guidance on the anesthetic management and pharmacological optimization of patients with valvular heart disease undergoing noncardiac surgery to prevent perioperative adverse events.
This review provides guidance on the perioperative anesthetic management and pharmacological optimization of patients with valvular heart disease undergoing noncardiac surgery.
Provides expert guidance for valvular patients in noncardiac surgery; leaves open the need for prospective validation before practice change.
Valvular heart disease can be an important finding in patients presenting for noncardiac surgery. Valvular heart disease and resulting comorbidity, such as heart failure or atrial fibrillation, significantly increase the risk for perioperative adverse events. Appropriate preoperative assessment, adequate perioperative monitoring, and early intervention, should hemodynamic disturbances occur, may help prevent adverse events and improve patient outcome. This review article aims to guide the practitioner in the various aspects of anesthetic management in the perioperative care of patients with valvular heart disease. The pharmacological approach to optimization of patient outcome with drugs, such as betablockers and lipid-lowering medications (statins), is an evolving field, and recent developments are discussed in this article.
No takes yet. Share an insight, caveat, or question.
Mittnacht et al. (2008) conducted a review in Valvular heart disease undergoing noncardiac surgery. Anesthetic management and pharmacological optimization was evaluated. This review provides guidance on the anesthetic management and pharmacological optimization of patients with valvular heart disease undergoing noncardiac surgery to prevent perioperative adverse events.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: